Loading mutual fund details…
BAJAJ FINSERV HEALTHCARE FUND - DIRECT - GROWTH is an equity scheme managed by Bajaj Finserv Mutual Fund. The total expense ratio is 0.78% on assets of ₹323Cr. The fund is currently managed by Mr. Sorbh Gupta, appointed within the last year.
Lower is better.
This scheme classifies as Large-Blend on the 3x3 equity style box, with 82% of its portfolio classified as of 2026-05-29.
| Holding | Sector |
|---|
| Window | Min | P25 | Median |
|---|
Point-in-time CAGRs cherry-pick a single start date. The chart below shows the distribution of every possible rolling start over the fund's history, so you see the range of investor outcomes — not just one date's number.
Backtested SIP outcomes across both rolling-window scenarios and named historical stress events (COVID, Election uncertainty, Russia/Ukraine, etc.), plus per-manager alpha during their tenure on this scheme.
Same fund, monthly SIPs over rolling 1/3/5-year windows.
Mutual fund investments are subject to market risks. Read all scheme-related documents carefully. Past performance is not indicative of future results. MintByte is an AMFI-registered Mutual Fund Distributor (ARN-314872) and APMI member (APRN-01658). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Star ratings on this page reflect a 3-year category-quartile position computed in-house and are educational only.
Mutual fund schemes are subject to market risk. Read all scheme-related documents carefully before investing. Past performance is not indicative of future results. MintByte is an AMFI-registered mutual fund distributor (ARN-314872). MintByte does not issue buy/sell recommendations on specific securities — the site is an educational data and analytics platform. Not investment advice. Methodology · How we earn.
In-house derivations using 3-year daily NAV vs benchmark. See methodology.
| Weight |
|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. | Healthcare | 8.83% |
| CIPLA LIMITED | Healthcare | 8.33% |
| APOLLO HOSPITALS ENTERPRISE LIMITED | Healthcare | 5.76% |
| PIRAMAL PHARMA LIMITED | Healthcare | 3.71% |
| BIOCON LIMITED | Healthcare | 3.66% |
| NEULAND LABORATORIES LIMITED | Healthcare | 2.98% |
| EMCURE PHARMACEUTICALS LIMITED | Healthcare | 2.70% |
| SYNGENE INTERNATIONAL LIMITED | Healthcare | 2.69% |
| TORRENT PHARMACEUTICALS LIMITED | Healthcare | 2.62% |
| GLAXOSMITHKLINE PHARMACEUTICALS LTD | Healthcare | 2.44% |
| IPCA LABORATORIES LIMITED | Healthcare | 2.28% |
| HINDUSTAN UNILEVER LIMITED | Consumer Defensive | 2.15% |
| SANOFI CONSUMER HEALTHCARE INDIA LIMITED | Healthcare | 2.02% |
| ABBOTT INDIA LIMITED | Healthcare | 1.89% |
| VIJAYA DIAGNOSTIC CENTRE LIMITED | Healthcare | 1.83% |
| ORCHID PHARMA LIMITED | Healthcare | 1.82% |
| ZYDUS WELLNESS LIMITED | Consumer Defensive | 1.81% |
| GLENMARK PHARMACEUTICALS LIMITED | Healthcare | 1.80% |
| PFIZER LIMITED | Healthcare | 1.78% |
| ALKEM LABORATORIES LIMITED | Healthcare | 1.57% |
| EMAMI LIMITED | Consumer Defensive | 1.52% |
| LUPIN LIMITED | Healthcare | 1.32% |
| ASTRAZENECA PHARMA INDIA LIMITED | Healthcare | 1.27% |
| MARICO LIMITED | Consumer Defensive | 1.21% |
| MEDPLUS HEALTH SERVICES LIMITED | Consumer Cyclical | 1.15% |
| Sector | Holdings | Weight |
|---|---|---|
| Healthcare | 25 | 81.63% |
| Fast Moving Consumer Goods | — | 8.40% |
| Consumer Services | — | 1.15% |
| Financial Services | — | 1.05% |
| Capital Goods | — | 0.48% |
| Chemicals | — | 0.46% |
Active bets vs the average Equity fund. Biggest deviations shown first.
Accent bar = fund's actual sector weight. Vertical black tick = category average for the same sector. Green overlay = overweight, dashed red = underweight. The biggest active bets show first.
| P75 |
|---|
| Max |
|---|
| Positive % |
|---|
| 1Y | -4.21% | 0.74% | 6.29% | 10.12% | 15.76% | 78.6% |
Top-10 weight 43.7% means the portfolio is broad — even the top names don't dominate. Effective-N is the inverse Herfindahl index — a measure of "how many positions effectively drive the fund" after weighting. Category: Equity.
Compounding maths on a notional ₹10 lakh lumpsum at 12% gross annual return. Green bar is what you'd have without the fee; red overlay is the fee drag. Fee is constant in this scenario — actual outcomes depend on real returns and any future TER changes.
What an investor SIPping into this fund actually got during named market shocks.
Each row is a back-tested SIP — monthly contribution over the regime's duration, no fees adjustment beyond NAV-baked TER. XIRR is the annualised IRR of those cashflows; Abs return is the absolute cash-on-cash; Max DD is the deepest drawdown experienced mid-investment. Past performance is not indicative of future results.
Alpha is the annualised excess return vs benchmark over the manager's tenure on this scheme. Beat-benchmark = total return beat the index over the same window.
Does the fund get worse as it gets bigger? Each dot is one historical manager-tenure: AUM at tenure-end vs alpha delivered during that tenure.
Correlation is too weak to confirm or rule out capacity-driven alpha decay. Re-evaluate as more manager-tenure data accumulates.
Each dot is one manager-tenure: X = AUM at tenure end, Y = alpha during that tenure. Connecting line in chronological order. Pearson r measures the linear relationship between AUM and alpha across the historical record. n = 3 data points.